ClinConnect ClinConnect Logo
Search / Trial NCT03876847

Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics)

Launched by INTERMOUNTAIN HEALTH CARE, INC. · Mar 13, 2019

Trial Information

Current as of August 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

For this study, we will ascertain clinical data and biological samples from a cohort of SCAD patients identified using retrospective review of medical records and prospective surveillance of Intermountain patients that undergo coronary angiography. The SCAD diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by two cardiologists and a third cardiologist in case of disagreement. It is anticipated that we hope to recruit 100 SCAD patients.

Enrollment of these subjects will be done under the INSPIRE registry. The subjects will be a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • SCAD Cases
  • 1. Subjects of all ages, gender, or race
  • 2. Subjects had coronary angiography.
  • 3. Subjects had suspected SCAD as based on clinical report.
  • Controls
  • 1. INSPIRE subject that had coronary angiography at Intermountain Healthcare for stable angina.
  • 2. Subjects had no or mild atherosclerotic heart disease at time of angiography.
  • 3. Age at last visit as recorded in the Intermountain EDW at least 50 years or older.
  • 4. Not screened as possibly having a SCAD or coronary artery dissection diagnosis.
  • Exclusion Criteria:
  • SCAD Cases
  • 1. Independent review of cardiac imaging and clinical presentation by three cardiologists determine the coronary angiography was not a result of SCAD.
  • 2. Imaging from time of coronary angiography of poor quality as to not allow for proper determination of SCAD.
  • 3. Inability to determine criteria as outlined above.
  • 4. Subjects that have had a heart transplant.
  • 5. Subjects that have had a bone marrow transplant.
  • 6. Inability or refusal of the patient and/or the patient's legally acceptable representative to provide informed consent or blood sample for any reason.
  • 7. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the trial.
  • Controls
  • 1. Subjects that have a heart transplant.
  • 2. Subjects that have a bone marrow transplant.
  • 3. Subjects with any of the following diagnosis at anytime
  • 1. Heart failure
  • 2. Heart valve disease
  • 3. Thoracic aortic aneurysm and dissection
  • 4. Ehlers-Danlos syndrome
  • 5. Shprintzen-Goldberg syndrome
  • 6. Marfan syndrome
  • 7. Loeys-Dietz aortic aneurysm syndrome
  • 8. Arterial tortuosity syndrome

About Intermountain Health Care, Inc.

Intermountain Health Care, Inc. is a leading nonprofit healthcare system based in Salt Lake City, Utah, dedicated to improving community health through innovative clinical practices and rigorous research initiatives. With a commitment to evidence-based care and patient-centered approaches, Intermountain actively sponsors clinical trials that aim to advance medical knowledge and enhance treatment options across various health conditions. The organization leverages its extensive network of hospitals, outpatient facilities, and specialized care services to facilitate high-quality research while prioritizing patient safety and ethical standards. Through collaboration with healthcare professionals and academic institutions, Intermountain Health Care strives to contribute significantly to the advancement of healthcare practices and outcomes.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials